A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT06617000 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2024-09-27
Summary
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
Conditions
- HCC
- Hepatitis B Virus Related Hepatocellular Carcinoma
- Hepatocellular Carcinoma
Interventions
- BIOLOGICAL
-
SCG101
Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
Sponsors & Collaborators
-
SCG Cell Therapy Pte. Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-25
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
NCT02686372 ·Status: COMPLETED ·Phase: PHASE1
-
TCR-Redirected T Cells Therapy in Patient With HBV Related HCC
NCT03899415 ·Status: UNKNOWN ·Phase: PHASE1
-
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
NCT06757881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
NCT04745403 ·Status: RECRUITING ·Phase: PHASE1
-
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
NCT05738447 ·Status: UNKNOWN ·Phase: PHASE1
-
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
NCT05609695 ·Status: UNKNOWN
-
Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy
NCT07186010 ·Status: RECRUITING
-
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
NCT06251115 ·Status: RECRUITING ·Phase: NA
-
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors
NCT04951141 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
NCT06408753 ·Status: COMPLETED
-
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma
NCT05070156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma
NCT03908840 ·Status: UNKNOWN ·Phase: PHASE1
-
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions
NCT06881446 ·Status: COMPLETED
-
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
NCT06537908 ·Status: RECRUITING
-
Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
NCT06639971 ·Status: NOT_YET_RECRUITING
-
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
NCT05620706 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
NCT06463522 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)
NCT03086564 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
NCT06560827 ·Status: RECRUITING ·Phase: PHASE1
-
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma
NCT06715072 ·Status: NOT_YET_RECRUITING
-
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
NCT02715362 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
NCT06652243 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
NCT03175679 ·Status: COMPLETED ·Phase: PHASE1
-
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546 ·Status: RECRUITING ·Phase: PHASE1
-
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
NCT05178043 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2